KFDA finally to determine Bio equivalency test review.

Published: 2006-09-25 06:58:00

Updated: 2006-09-25 06:58:00

The KFDA finally determined that the bio equivalency tests for the total 600 drugs including 200 cases with uninterpretable data and 400 cases of no data should be reviewed after consultation with the legal experts, pharmaceutical circles and consumer groups. During the reviewing period, those dr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK